Hematology Course: Introduction and Hematopoiesis

Introduction to Hematopoiesis

Hematopoiesis, also referred to as hemopoiesis, is defined as the well-controlled and continuous process of blood cell formation, production, differentiation, and development. This process serves two primary physiological purposes:

• To replenish dying cells with new blood cells.
• To enable the body to respond to increased demands, such as those caused by bleeding or infection.

The process is categorized based on the specific lineage of cells being produced:

• Erythropoiesis: The formation of red blood cells (RBCs).
• Myelopoiesis: The formation of white blood cells (WBCs), specifically granulocytes and monocytes.
• Thrombopoiesis: The formation of platelets.

Developmental Stages of Hematopoiesis

Hematopoiesis occurs in different anatomical locations depending on the stage of life, characterized as prenatal and postnatal hemopoiesis.

Prenatal Hemopoiesis

• Yolk Sac: Activity begins very early in gestation and peaks within the first two fetal months, then rapidly declines.
• Liver: Becomes the primary site of hematopoiesis from the second to seventh fetal months, peaking around the fifth month.
• Spleen: Contributes to hematopoiesis from roughly the third to sixth fetal months.
• Bone Marrow: Hematopoiesis starts in the bone marrow around the fourth fetal month and becomes the dominant site from the seventh month through birth.

Postnatal Hemopoiesis

Following birth, hematopoiesis is primarily restricted to the bone marrow. The cellularity and location of active marrow change with age:

• Long Bones (Tibia and Femur): These are highly active in infancy and childhood. Significant activity in the tibia typically ceases around age 20. Activity in the femur declines and largely disappears by age 25.
• Axial Skeleton: In adults, hematopoiesis is sustained throughout life in the vertebrae, sternum, ribs, and pelvis.

Stem Cell Concepts and Differentiation

Hematopoiesis is derived from pluripotential stem cells that possess two fundamental properties:

1. Self-Renewal: The ability of the stem cell to produce more stem cells of the same type, maintaining the stem cell pool.
2. Differentiation: The process of becoming a specialized cell type.

Hierarchy of Stem Cells

• Pluripotential Stem Cell (Totipotent): A master cell capable of giving rise to any type of cell. Its specific function is determined by the tissue environment in which it exists.
• Hemopoietic Stem Cell (HSC): A subtype of the pluripotential stem cell that is committed specifically to giving rise only to blood cells (RBCs, WBCs, and platelets).
• Multipotent Progenitor Cells: Descendants of HSCs that have lost some pluripotency but can still give rise to multiple lineages.
• Committed Marrow Precursors: Recognizable cells that are restricted to a single lineage.
• Mature Cells: The final, specialized cells circulating in the blood.

As bone marrow cells become increasingly differentiated and mature, they lose their capacity for self-renewal.

Regulation of Hematopoiesis

The process is tightly regulated by various growth factors and cytokines, which can be categorized by their specificity:

Non-Lineage Specific Factors

These act on early stem cells and multipotent progenitors to stimulate broad production:

• Stem Cell Factor (SCF)
• Interleukin-3 (IL-3)

Lineage-Specific Factors

These act on committed precursors to drive the production of specific cell types:

• Erythropoietin (Epo): Regulates erythropoiesis.
• Granulocyte-Colony Stimulating Factor (G-CSF): Regulates granulopoiesis (neutrophils).
• Thrombopoietin (Tpo): Regulates the production of platelets.

Stem Cell Mobilization

While HSCs are mostly concentrated in the bone marrow, they can be induced to circulate in the peripheral blood by the administration of G-CSF.

Extramedullary Hematopoiesis

Extramedullary hematopoiesis refers to the reactivation of hematopoietic islands in organs outside the bone marrow, such as the liver and spleen. This occurs whenever the bone marrow is:

1. Incapable of meeting physiological demands (e.g., in severe hemolytic anemias).
2. Infiltrated by malignant cells (e.g., in leukemia).
3. Replaced by fibrous tissue (e.g., in myelofibrosis).

Erythropoiesis and Erythrocytic Maturation

The maturation of red blood cells follows a specific sequence in the bone marrow. The nucleated precursors are known as normoblasts, erythroblasts, or nucleated red blood cells (NRBCs). These cells are not present in normal human peripheral blood.

Reticulocytes

Reticulocytes are non-nucleated red cells that still contain residues of ribosomal RNA in the cytoplasm.

• Normal Ranges:
  • Adults: $0.5\% - 2.0\%$
  • Newborn infants: $2.5\% - 6.0\%$
• Appearance: On a standard blood smear, they show polychromasia (a bluish tint). When stained with a supravital stain, they exhibit a characteristic reticular (net-like) appearance due to the precipitated RNA.

Fundamentals of Erythropoiesis

The process requires several components:

1. The Factory: An active bone marrow containing healthy stem cells, Burst-Forming Unit-Erythroid (BFU-E), and Colony-Forming Unit-Erythroid (CFU-E).
2. Nutrients: Essential building blocks including Iron ($Fe$), Vitamin $B_{12}$, Folate, and other vitamins.
3. Growth Factor: Erythropoietin (Epo).

Erythropoietin (Epo) Dynamics

Erythropoietin is produced by peritubular interstitial cells in the outer cortex of the kidney. Its production is controlled by oxygen ($O_2$) sensors involving Hypoxia-Inducible Factors (HIF-$\alpha$ and $\beta$).

Stimulation and Inhibition

• Epo production increases in response to tissue hypoxia, which can be caused by anemia, high altitude (atmospheric $O_2$), cardiac/pulmonary dysfunction, or shifts in the $O_2$-dissociation curve.
• Epo production decreases in cases of renal failure, high $O_2$ tension, or a high red cell mass.
• Specific Effects: Epo stimulates new vessel formation, increases iron absorption, inhibits hepcidin synthesis, and promotes transferrin receptor synthesis.

Recombinant Human Erythropoietin

Pharmaceutical versions include Erythropoietin alpha or beta, Darbepoetin alpha, and Micera. These treatments often require supplemental intravenous iron. Side effects may include a rise in blood pressure and thrombosis.

Indications for Epo Therapy:

1. Anemia of chronic renal disease.
2. Myelodysplastic syndrome (MDS).
3. Anemia associated with malignancy and chemotherapy.
4. Anemia of chronic diseases (e.g., rheumatoid arthritis).
5. Anemia of prematurity.

Myelopoiesis and Myeloid Maturation

The first recognizable granulocyte precursor in the bone marrow is the myeloblast. The maturation sequence for neutrophils is: $\text{Myeloblast} \rightarrow \text{Promyelocyte} \rightarrow \text{Myelocyte} \rightarrow \text{Metamyelocyte} \rightarrow \text{Band form} \rightarrow \text{Neutrophil}$

Functions of G-CSF

G-CSF regulates myeloid development through four mechanisms:

1. Proliferation: Increases the total number of cells.
2. Differentiation: Enhances maturation and shortens maturation time.
3. Suppression of Apoptosis: Leads to longer survival of mature cells.
4. Functional Activation: Improves the performance of mature cells by activating phagocytosis, killing, and secretion.

Clinical Applications of G-CSF

1. Neutropenia: Management after chemotherapy or radiotherapy, and following stem cell transplantation (SCT).
2. Congenital cyclic neutropenia.
3. Peripheral blood stem cell mobilization.

Clinical Terminology and Blood Film Reporting

Left Shift

A morphological description of the release of immature granulocytes from the bone marrow into the peripheral blood.

• Mild-Moderate Left Shift (Bandemia): Mostly band forms; often a sign of infection.
• Severe Left Shift: Release of earlier precursors (myelocytes, metamyelocytes, or even myeloblasts) into the peripheral blood due to severe infection or G-CSF administration.

Leukoerythroblastic Reaction

This refers to the abnormal release of immature precursors of both myeloid and erythroid cell lines (e.g., myeloblasts and nucleated RBCs) into the peripheral blood. It indicates a significant disturbance of marrow function. Causes include:

• Bone marrow metastasis.
• Myelofibrosis (MF).
• Leukemias (AML, CML).
• Multiple Myeloma (MM).
• Reactive states such as severe hemorrhage or hemolysis.
• Corticosteroid therapy. It is often an indication for a bone marrow study.

Neutrophilic Leukocytosis (Neutrophilia)

Defined by a total WBC count greater than $11,000/mm^3$ ($11 \times 10^9 / L$) or an absolute neutrophil count (ANC) greater than $7,500/mm^3$ ($7.5 \times 10^9 / L$), which typically constitutes more than $70\%$ of the WBC differential. Causes include smoking, infection (bacterial/fungal), inflammation, necrosis, hemorrhage, drugs (lithium, glucocorticoids, epinephrine), and Down syndrome.

Leukemoid Reaction

An excessive reactive leukocytosis where the WBC count reaches up to $50,000/mm^3$ ($50 \times 10^9 / L$). It is a benign proliferation involving increased numbers of both mature forms and immature precursors (blasts, myelocytes, metamyelocytes). Differential diagnosis must distinguish it from acute or chronic leukemia. It is commonly triggered by severe infection, metastatic cancer, hemolysis, or burns.

Questions & Case Scenarios

Case 1: Fever and High WBC

• Patient: 22-year-old male with fever for 1 month.
• Findings: WBC count of $14,000/mm^3$ with neutrophils, band forms, myelocytes, metamyelocytes, and myeloblasts.
• Classification: This represents a Leukemoid Reaction or severe left shift. Given the duration and presence of blasts, acute leukemia must be considered in the differential diagnosis.

Case 2: Low WBC and Immature Cells

• Patient: 55-year-old female with recurrent infection.
• Findings: WBC count of $1,000/mm^3$ (leukopenia). The film shows neutrophils, band forms, myelocytes, metamyelocytes, myeloblasts, and nucleated RBCs.
• Classification: This is a Leukoerythroblastic picture combined with leukopenia, suggesting a significant bone marrow pathology such as infiltration or failure.